| Page 53 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study

Author(s): 
Rogers ZR, Nakano TA, Olson TS, Bertuch AA, Wang W, Gillio A, Coates TD, Chawla A, Castillo P, Kurre P, Gamper C, Bennett CM, Joshi S, Geddis AE, Boklan J, Nalepa G, Rothman JA, Huang JN, Kupfer GM, Cada M, Glader B, Walkovich KJ, Thompson AA, Hanna R
Primary Author: 
Rogers ZR
Journal Title: 
Haematologica
Original Publication Date: 
Apr 2019

Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe

Bone Marrow Disease(s): 

Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution

Author(s): 
Winkler T, Fan X, Cooper J, Desmond R, Young DJ, Townsley DM, Scheinberg P, Grasmeder S, Larochelle A, Desierto M, Valdez J, Lotter J, Wu C, Shalhoub RN, Calvo KR, Young NS, Dunbar CE
Primary Author: 
Winkler T
Journal Title: 
Blood
Original Publication Date: 
Apr 2019

Eltrombopag received FDA approval for the treatment of refractory severe

Bone Marrow Disease(s): 

Getting personal with myelodysplastic syndromes: is now the right time?

Author(s): 
Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM
Primary Author: 
Chokr N
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Apr 2019

Commonly used scoring systems rely on blood counts, histological and cytological examination of

Bone Marrow Disease(s): 

Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

Author(s): 
Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM
Primary Author: 
Stahl M
Journal Title: 
Haemotologica
Original Publication Date: 
Apr 2019

Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk

Bone Marrow Disease(s):